PN2034

DRUG2 trials

Sponsors

Wellstat Therapeutics

Conditions

Type 2 Diabetes Mellitus

Phase 2

Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet)

CompletedNCT00110851

Wellstat TherapeuticsType 2 Diabetes Mellitus

Start: 2005-04-30End: 2007-08-31Target: 90Updated: 2007-08-23

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

CompletedNCT00110864

Wellstat TherapeuticsType 2 Diabetes Mellitus

Start: 2005-05-31End: 2007-04-30Target: 90Updated: 2007-08-23